文章说q1今年收入1_老虎社区_美港股上老虎

Dorash
2021-03-24

文章说q1今年收入1千万

Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates

Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens

Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":351885004,"tweetId":"351885004","gmtCreate":1616584915408,"gmtModify":1616584915408,"author":{"id":3464149602391943,"idStr":"3464149602391943","authorId":3464149602391943,"authorIdStr":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>文章说q1今年收入1千万</p></body></html>","htmlText":"<html><head></head><body><p>文章说q1今年收入1千万</p></body></html>","text":"文章说q1今年收入1千万","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/351885004","repostId":2120700679,"repostType":2,"repost":{"id":"2120700679","kind":"news","pubTimestamp":1615930509,"share":"https://www.laohu8.com/m/news/2120700679?lang=&edition=full","pubTime":"2021-03-17 05:35","market":"us","language":"en","title":"Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2120700679","media":"Zacks","summary":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens","content":"<html><body><p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.</p>\n<p>Over the last four quarters, the company has surpassed consensus EPS estimates two times.</p>\n<p>Kindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Kindred Bio shares have added about 13.7% since the beginning of the year versus the S&amp;P 500's gain of 5%.</p>\n<p><b>What's Next for Kindred Bio?</b></p>\n<p>While Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p>\n<p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p>\n<p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p>\n<p>Ahead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p>\n<p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.</p>\n<p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\n<a href=\"https://laohu8.com/S/KIN\">Kindred Biosciences, Inc.</a> (KIN) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/88Fg6KE6GPnh0zlh3tqRTA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","relate_stocks":{"KIN":"Kindred Biosciences, Inc."},"source_url":"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2120700679","content_text":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.\nOver the last four quarters, the company has surpassed consensus EPS estimates two times.\nKindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nKindred Bio shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 5%.\nWhat's Next for Kindred Bio?\nWhile Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\nThere are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\nEmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\nAhead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\nIt will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.\nInvestors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nKindred Biosciences, Inc. (KIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":1348,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":21,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}